Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290063 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol and Older Adult Cannabis Users
A Phase 2 study of Depression and Pain, sponsored by University of Colorado, Boulder.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 1
- Study location
NCT06290063: Recruiting Phase 2 study of Depression and Pain, sponsored by University of Colorado, Boulder.
NCT06290063 is a Phase 2 study of Depression and Pain that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 385 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290063, a Phase 2 study of Depression and Pain, is actively recruiting participants, sponsored by University of Colorado, Boulder.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.
Primary Outcome
Activities-specific Balance Confidence Scale. Participants asked about confidence in completion of 16 daily tasks without losing balance or becoming unsteady. Responses are on a scale from no confidence to completely confident, with higher aggregate scores meaning higher subjective motor function.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG fsCBD Cannabidiol
- DRUG bsCBD Cannabidiol
Study Locations (1)
Colorado
- University of Colorado at Boulder - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
What NCT06290063 shows while recruiting
NCT06290063 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (51% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06290063 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06290063 about?
NCT06290063 is a clinical study titled "Cannabidiol and Older Adult Cannabis Users". Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use c...
What is the current status of trial NCT06290063?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2024-05-01. Estimated completion is 2028-08-31.
What conditions does trial NCT06290063 study?
This clinical trial studies the following conditions: Depression, Pain, Anxiety, Sleep.
What interventions are being tested in trial NCT06290063?
The interventions under investigation include: Placebo (DRUG), fsCBD Cannabidiol (DRUG), bsCBD Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT06290063?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290063 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06290063's enrollment target sits among peer trials
385 114th of 679 higher than 566 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
-
Investigation to Understand and Optimize Psilocybin
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06226883 · 385 participants · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- NCT06431594 · 385 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy